HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

513.048

-0.450-0.09%

Number of Gainers:28

Number of Losers:19

Number of Flat:8

PE:- -

High:516.134

Open:513.498

Low:507.279

Close:513.498

Loading ...

JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment

JW (Cayman) Therapeutics - Nmpa Acceptance of Supplemental Biological License Application for Carteyva

THOMSON REUTERS

Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Ongericimab Injection by Nmpa

THOMSON REUTERS

BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use

Youzan Technology Ltd. Conducted Annual General Meeting

Peijia Medical Ltd. Concluded Annual General Meeting

Zylox-Tonbridge's ZYLOX Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia, Marking First International Market Clearance

Zylox Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia

THOMSON REUTERS

HBM Holdings Ltd. Files Next Day Disclosure with HKEX: 200,000 Shares Repurchased at HKD 8.3887 Each

Zylox-Tonbridge Files Next Day Disclosure to HKEX: Repurchases 6,285,000 Shares for HKD 933,230

WuXi AppTec Cuts Conversion Price of Zero-Coupon Bonds Due This Year

MT Newswires Live

Yunnan International Trust Co., Ltd. Sells Shares in Jinke Smart Services Group Co. Ltd. Amid Possible Mandatory General Offer

Anhui Conch Cement Signs 122 Million Yuan Engineering Design Contract With Subsidiary

MT Newswires Live

Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1583/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":513.04846,"timestamp":1749197315346,"preClose":513.49805,"halted":0,"volume":787771556,"delay":0,"changeRate":-0.000876,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-0.449585,"latestTime":"06-06 16:00:00","open":513.49805,"high":516.1344,"low":507.27917,"amount":15627538503,"amplitude":0.017245,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":2.358598,"peRate":21.998152,"turnoverRate":0.005389,"increases":30,"decrements":20,"flats":4,"marketCap":2901322639680,"floatMarketCap":2286727975232},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":516.1344,"amplitude":0.017245,"preClose":513.49805,"low":507.27917,"pbRate":"2.358598","latestPrice":513.04846,"volume":787771556,"delay":0,"open":513.49805,"prevYearClose":446.93042,"prevWeekClose":496.286,"prevMonthClose":496.286,"prevQuarterClose":505.776,"fiveDayClose":496.286,"twentyDayClose":480.539,"sixtyDayClose":530.16,"secType":"PLATE","market":"HK","turnoverRate":0.005389,"peRate":21.998152,"marketCap":2901322639680,"floatMarketCap":2286727975232,"timestamp":1749197315346,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":28,"down":19,"flat":8},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538423760","title":"JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2538423760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538423760?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:57","pubTimestamp":1748422651,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment. JW Cayman Therapeutics Co. Ltd., a biotechnology company specializing in cell immunotherapy products, has announced that the National Medical Products Administration of China  has accepted the supplemental Biological License Application  for Carteyva . The product is proposed as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma  who are ineligible for autologous stem cell transplantation. This marks the fourth sBLA submission for Carteyva by JW Therapeutics, reflecting the company's ongoing efforts in the development and commercialization of cell immunotherapy solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLbrjft9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02126","BK1583","BK1574"],"gpt_icon":0},{"id":"2538428296","title":"JW (Cayman) Therapeutics - Nmpa Acceptance of Supplemental Biological License Application for Carteyva","url":"https://stock-news.laohu8.com/highlight/detail?id=2538428296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538428296?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:35","pubTimestamp":1748421322,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","02126","BK1574"],"gpt_icon":0},{"id":"2538465968","title":"Shanghai Junshi Biosciences -  Approval of Supplemental New Drug Application for Ongericimab Injection by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465968","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465968?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:53","pubTimestamp":1748346824,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ10I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01877","688180","BK1161","BK0239","BK1583","BK1515"],"gpt_icon":0},{"id":"2538468004","title":"BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2538468004","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538468004?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:12","pubTimestamp":1748344320,"startTime":"0","endTime":"0","summary":"BeiGene's Tevimbra gets a highly sought after recommendation.The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use  issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer.Nasopharyngeal cancer is a type of head and neck cancer that starts in the upper throat passage that connects the nose to the lungs.Mark Lanasa, chief medical officer, solid tumors at BeiGene, said the announcement marks a second positive CHMP opinion for Tevimbra this year.Tevimbra is currently approved in the European Union as a first-line treatment for eligible patients with gastric or gastroesophageal junction adenocarcinoma, among other use cases.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","LU0307460666.USD","06160","BK4139","BK1161","BK1500","BK1588","BK4526","LU1969619763.USD","CHMP","LU2328871848.SGD","ONC","BK1583","LU0588546209.SGD"],"gpt_icon":0},{"id":"2538450236","title":"Youzan Technology Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538450236","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538450236?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:38","pubTimestamp":1748342283,"startTime":"0","endTime":"0","summary":"Youzan Technology Ltd. held its Annual General Meeting on 27 May 2025. All the resolutions proposed at the meeting were approved by the shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Youzan Technology Ltd. published the original content used to generate this news brief on May 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL2NLFc2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1590","BK1516","08083","BK1583","BK1518","BK1109"],"gpt_icon":0},{"id":"2538457934","title":"Peijia Medical Ltd. Concluded Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538457934","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538457934?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:04","pubTimestamp":1748340244,"startTime":"0","endTime":"0","summary":"Peijia Medical Ltd. held its Annual General Meeting on May 27, 2025. All resolutions proposed at the meeting were approved by the shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Peijia Medical Ltd. published the original content used to generate this news brief on May 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDLGh9XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","BK1574","BK1583","BK1100"],"gpt_icon":0},{"id":"2538348765","title":"Zylox-Tonbridge's ZYLOX Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia, Marking First International Market Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2538348765","media":"Reuters","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538348765?lang=en_us&edition=fundamental","pubTime":"2025-05-27 10:14","pubTimestamp":1748312068,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge's ZYLOX Unicorn Vascular Closure Device Receives Regulatory Approval in Indonesia, Marking First International Market Clearance. Zylox-Tonbridge Medical Technology Co., Ltd. has announced that its ZYLOX Unicorn Vascular Closure Device has received regulatory approval in Indonesia. This marks the first international market clearance for the device and represents Zylox-Tonbridge's initial market authorization in Southeast Asia. The approval in Indonesia, the world's fourth most populous country, will enhance access to advanced vascular intervention solutions for local physicians and patients. This milestone supports Zylox-Tonbridge's ongoing international expansion strategy, aiming to provide high-quality, affordable vascular care solutions globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL6gYXPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1100","BK1574","BK1587","BK1583"],"gpt_icon":0},{"id":"2538487991","title":"Zylox Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2538487991","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538487991?lang=en_us&edition=fundamental","pubTime":"2025-05-27 10:14","pubTimestamp":1748312057,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA1WNT3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1100","BK1587","BK1574","02190","BK1583"],"gpt_icon":0},{"id":"2538109181","title":"HBM Holdings Ltd. Files Next Day Disclosure with HKEX: 200,000 Shares Repurchased at HKD 8.3887 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2538109181","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538109181?lang=en_us&edition=fundamental","pubTime":"2025-05-26 21:37","pubTimestamp":1748266654,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, reporting the repurchase of 20,449,000 shares. The aggregate price paid for the repurchased shares is HKD 1,677,740. The shares were repurchased for holding as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL3p1s14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02142","BK1574","BK1161"],"gpt_icon":0},{"id":"2538088721","title":"Zylox-Tonbridge Files Next Day Disclosure to HKEX: Repurchases 6,285,000 Shares for HKD 933,230","url":"https://stock-news.laohu8.com/highlight/detail?id=2538088721","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538088721?lang=en_us&edition=fundamental","pubTime":"2025-05-26 18:57","pubTimestamp":1748257079,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting a repurchase of 6,285,000 shares. The total aggregate price paid for the repurchase was HKD 933,230.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL68v3fC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1100","02190","BK1587"],"gpt_icon":0},{"id":"2538793501","title":"WuXi AppTec Cuts Conversion Price of Zero-Coupon Bonds Due This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2538793501","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538793501?lang=en_us&edition=fundamental","pubTime":"2025-05-26 17:04","pubTimestamp":1748250265,"startTime":"0","endTime":"0","summary":"WuXi AppTec  will lower the conversion price of its $500 million zero-coupon convertible bonds due 2025, according to a Friday filing with the Hong Kong Exchange.As a result of shareholders' approval of the 2024 profit distribution and 2025 special dividend, the conversion price will drop from HK$80.02 to HK$78.28 per H Share, effective May 24.This adjustment increases the potential convertible shares from about 48.5 million to 49.6 million, representing roughly 12.81% of current issued shares and 11.36% after full conversion.Shares of the pharma company were down about 3% at market close on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1141","BK1576","LU2125910500.SGD","LU0320764599.SGD","LU0708995583.HKD","BK1583","LU0052750758.USD","02359","LU1046422090.SGD","LU2045819591.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2538175741","title":"Yunnan International Trust Co., Ltd. Sells Shares in Jinke Smart Services Group Co. Ltd. Amid Possible Mandatory General Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2538175741","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538175741?lang=en_us&edition=fundamental","pubTime":"2025-05-26 16:59","pubTimestamp":1748249947,"startTime":"0","endTime":"0","summary":"Yunnan International Trust Co., Ltd. Sells Shares in Jinke Smart Services Group Co. Ltd. Amid Possible Mandatory General Offer. Jinke Smart Services Group Co. Ltd. announced internal dealings under Rule 22 of the Hong Kong Code on Takeovers and Mergers. On 23 May 2025, Yunnan International Trust Co., Ltd. sold a total of 24,000 shares in Jinke Smart Services Group. The resultant balance of shares held by Yunnan International Trust stands at 9,634,400, representing 1.6136% of the class. Yunnan International Trust is associated with the Offeree company through a defined class of acting in concert and is ultimately owned by Yunnan Provincial State-owned Financial Capital Holding Group Co., Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL1kN6ch:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1258","BK0028","BK1229","000656","BK1542","BK0174","BK0273","BK1583","09666","BK0188"],"gpt_icon":0},{"id":"2538127766","title":"Anhui Conch Cement Signs 122 Million Yuan Engineering Design Contract With Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2538127766","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538127766?lang=en_us&edition=fundamental","pubTime":"2025-05-26 15:26","pubTimestamp":1748244372,"startTime":"0","endTime":"0","summary":"Anhui Conch Cement  entered into a 121.9 million yuan contract on behalf of its relevant subsidiaries, according to a Hong Kong bourse filing on May 23.Under the contract, the cement maker's subsidiary, Anhui Conch Construction Materials Design Institute, will provide engineering design and technology modification services for projects owned by the company and some of its units.The projects include manufactured sand, commodity concrete projects, clinker lines, grinding stations, slag powder transit projects, large-scale special modification projects, and various engineering consulting services.The contract followed a 37.1 million yuan limestone mine infrastructure project signed in February and a 17.6 million yuan selective catalytic reduction denitration project signed in November 2024, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK1507","BK1594","BK0044","BK0187","BK0235","600585","LU1328615791.USD","BK0015","BK0196","BK1505","00914","BK0012","BK1563","BK0028","BK0183","BK1583","BK1135"],"gpt_icon":0},{"id":"2538808141","title":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2538808141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538808141?lang=en_us&edition=fundamental","pubTime":"2025-05-26 08:00","pubTimestamp":1748217619,"startTime":"0","endTime":"0","summary":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire  on May 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL3LGflG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1147","BK1583","LU2328871848.SGD","BK1161","LU1969619763.USD","BK1589","01801","01911"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":94,"code":"91000000","status":"200"}]}}